Melola Discovery

← Melola Discovery

Journal SINTA 1

Review Article and Clinical Experience: Hypertension in Diabetic Nephropathy. The Five “Satan Circles”, DHA-LiCOAR, the Roles of Valsartan

Folia Medica Indonesiana · Vol. 43 No. 2 (2007)

ISSN
2355-8393, 2599-056X
Published
2007-04-01
Publisher
Airlangga University
Language
en

Abstract

On the basis of clinical experiences, 5 (five) “Satan Vicious Circles” in diabetic nephropathy (DN) are summarized. These vicious circles should be well recognized to understand the pathogenesis of DN, and to perform its rationale treatment. The 1st “Satan Circle” hypertension –– proteinuria –– glomerular injury –– and then to hypertension again. The 2nd “Satan Circle” GLUT-1 –– glucose –– TGF- β –– and then to GLUT-1 again. The 3rd “Satan Circle” AII –– TGF- β –– PAI-1 –– and then to AII again. The 4th “Satan Circle” AII –– PKC –– AI –– and then to AII again. The 5th “Satan Circle” or the “Deadly Satan Circle” (frequently happens in hemodyalized-patients). Dialysate, Membrane, and AOPP these three components altogether stimulate the production of cytokines (VCAM1, MCP1, etc) –– NADPH oxidase –– increased ROS and RONS production –– activated NFkB/API/MAPK –– and then to cytokines (VCAM1, MCP1, etc) again. ROS and RONS also stimulate the production of MMP9. On the basis of clinical experiences in Surabaya, “DHA-LiCOAR” (Diabetes, Hypertension, Albuminuria – Lipid, Cigarette, Obesity, Antiplatelet, Renal replacement therapy) can be used as practical guideline for the treatment of patients with DN. MARVAL and VALUE are the two landmark studies of valsartan which favours microalbuminuria reduction of patients with DN and lower incidence of new-onset of diabetes, respectively. The results of MARVAL indicate a blood pressure-independent antiproteinuric effects of valsartan (blood pressure-independent effect). Compared with amlodipine, valsartan significantly lowered urinary albumin excretion rate of T2DM with microalbuminuria (-8% in amlodipine vs -44% in valsartan treated, p < 0.001). At 24-weeks, valsartan treated patients showed 29.9% reversion to normoalbuminuria compared with 14.5% in amlodipine treated patients (p < 0.001). In the VALUE study, valsartan showed 23% risk reduction of the new-onset diabetes (p < 0.0001). There was no significant difference in the outcomes in hypertensive patients at high cardiovascular risk treated with regiments based on valsartan or amlodipine. Valsartan (a highlyselective ARB) improved “DHA” (the three essential components), and hence this ARB is in favour of the treatment of patients with diabetic nephropathy.

Keywords

Collaboration network of the authors

8 authors · 16 co-authorship links · 7 across different organisations

Hover or tap a name to highlight its co-authors. Double-click to open the author's page.

  • Universitas Airlangga
  • University of Brawijaya
  • Rumah Sakit Umum Pusat Dr. Sardjito
  • Affiliation unknown
  • Different organisations
  • Same organisation
  • Affiliation unknown
  • Thicker line = more joint articles · bigger circle = more articles
Show as table
Co-authorOrganisationJoint articles
Agung Sindu PranotoUniversitas Airlangga1
Hermina NovidaUniversitas Airlangga1
Jongky Hendro PrayitnoAffiliation unknown1
Adeodatus Yuda HandayaRumah Sakit Umum Pusat Dr. Sardjito1
Djanggan SargowoUniversity of Brawijaya1
Diana LyrawatiUniversity of Brawijaya1
Mohammad Aris WidodoUniversity of Brawijaya1

Affiliations come from OpenAlex; journal OAI-PMH metadata carries none. Authors without an OpenAlex ID are matched by name, which can merge or split people.

Metadata source: OpenAlex API (jurnal SINTA, ADR 0048) https://openalex.org/S4210179714, first harvested 19 Nov 2026, last seen 19 Nov 2026.
Original metadata (oai_dc)
<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"><dc:title xml:lang="en">Review Article and Clinical Experience: Hypertension in Diabetic Nephropathy. The Five “Satan Circles”, DHA-LiCOAR, the Roles of Valsartan</dc:title><dc:creator>Askandar Tjokroprawiro</dc:creator><dc:subject>diabetic nephropathy</dc:subject><dc:subject>hypertension</dc:subject><dc:subject>proteinuria</dc:subject><dc:subject>vicious circle</dc:subject><dc:subject>valsartan</dc:subject><dc:subject>angiotensin II</dc:subject><dc:subject>TGF-beta</dc:subject><dc:subject>plasminogen activator inhibitor-1</dc:subject><dc:subject>protein kinase C</dc:subject><dc:subject>albuminuria</dc:subject><dc:subject>hemodialysis</dc:subject><dc:subject>dialysate</dc:subject><dc:subject>oxidative stress</dc:subject><dc:subject>NADPH oxidase</dc:subject><dc:subject>cytokines</dc:subject><dc:subject>values</dc:subject><dc:subject>amlodipine</dc:subject><dc:subject>microalbuminuria</dc:subject><dc:subject>renal protection</dc:subject><dc:description xml:lang="en">On the basis of clinical experiences, 5 (five) “Satan Vicious Circles” in diabetic nephropathy (DN) are summarized. These vicious circles should be well recognized to understand the pathogenesis of DN, and to perform its rationale treatment. The 1st “Satan Circle” hypertension –– proteinuria –– glomerular injury –– and then to hypertension again. The 2nd “Satan Circle” GLUT-1 –– glucose –– TGF- β –– and then to GLUT-1 again. The 3rd “Satan Circle” AII –– TGF- β –– PAI-1 –– and then to AII again. The 4th “Satan Circle” AII –– PKC –– AI –– and then to AII again. The 5th “Satan Circle” or the “Deadly Satan Circle” (frequently happens in hemodyalized-patients). Dialysate, Membrane, and AOPP these three components altogether stimulate the production of cytokines (VCAM1, MCP1, etc) –– NADPH oxidase –– increased ROS and RONS production –– activated NFkB/API/MAPK –– and then to cytokines (VCAM1, MCP1, etc) again. ROS and RONS also stimulate the production of MMP9. On the basis of clinical experiences in Surabaya, “DHA-LiCOAR” (Diabetes, Hypertension, Albuminuria – Lipid, Cigarette, Obesity, Antiplatelet, Renal replacement therapy) can be used as practical guideline for the treatment of patients with DN. MARVAL and VALUE are the two landmark studies of valsartan which favours microalbuminuria reduction of patients with DN and lower incidence of new-onset of diabetes, respectively. The results of MARVAL indicate a blood pressure-independent antiproteinuric effects of valsartan (blood pressure-independent effect). Compared with amlodipine, valsartan significantly lowered urinary albumin excretion rate of T2DM with microalbuminuria (-8% in amlodipine vs -44% in valsartan treated, p &lt; 0.001). At 24-weeks, valsartan treated patients showed 29.9% reversion to normoalbuminuria compared with 14.5% in amlodipine treated patients (p &lt; 0.001). In the VALUE study, valsartan showed 23% risk reduction of the new-onset diabetes (p &lt; 0.0001). There was no significant difference in the outcomes in hypertensive patients at high cardiovascular risk treated with regiments based on valsartan or amlodipine. Valsartan (a highlyselective ARB) improved “DHA” (the three essential components), and hence this ARB is in favour of the treatment of patients with diabetic nephropathy.</dc:description><dc:publisher>Airlangga University</dc:publisher><dc:date>2007-04-01</dc:date><dc:type>info:eu-repo/semantics/article</dc:type><dc:identifier>https://journal.unair.ac.id/download-fullpapers-11%20Askandar0702%20_format%20FMI_.pdf</dc:identifier><dc:source>Folia Medica Indonesiana; Vol 43 No 2 (2007)</dc:source><dc:source>2355-8393</dc:source><dc:source>2599-056X</dc:source><dc:language>en</dc:language></oai_dc:dc>